Search Within

Gastrointestinal Oncology Service

Formats
  1. Journal Article (2351)
  2. Meeting Abstract (1870)
  3. Review (150)
  4. Book Section (127)
  5. Editorial (101)
  6. Guidelines (40)
  7. Correspondence (34)
  8. Conference Paper (24)
  9. Miscellaneous (23)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Solid Tumor Oncology Division (4749)
  2. Department of Medicine (4747)
  3. Center for Pancreatic Cancer Research (2316)
  4. Surgery (1067)
  5. Survivorship Research (1014)
  6. Epidemiology and Biostatistics (843)

More Groups

People
  1. Eileen O'Reilly (804)
  2. Leonard Saltz (796)
  3. Ghassan Abou-Alfa (583)
  4. Nancy Kemeny (545)
  5. David Kelsen (538)
  6. David Ilson (443)

More People

Years
  1. 2025 (224)
  2. 2024 (309)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1290)
  2. Annals of Oncology (331)
  3. Annals of Surgical Oncology (148)
  4. Cancer (128)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1379)
  2. Oxford University Press (462)
  3. Elsevier Inc. (408)
  4. Springer (322)
  5. American Association for Cancer Research (281)
  6. Wiley Blackwell (241)

More Publishers

Results (4749)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The current status of immunotherapies in esophagogastric cancer
    Review

    Ku, G. Y.
    Hematology/Oncology Clinics of North America (2019)

    Fulltext@MSK | Save
  • KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer
    Review

    Bang, Y. J.; Van Cutsem, E.; Fuchs, C. S.; Ohtsu, A.; Tabernero, J.; Ilson, D. H.; Hyung, W. J.; Strong, V. E.; Goetze, T. O.; Yoshikawa, T.; more...
    Future Oncology (2019)

    Fulltext@MSK | Save
  • Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial
    Journal Article

    Kosumi, K.; Hamada, T.; Zhang, S.; Liu, L.; da Silva, A.; Koh, H.; Twombly, T. S.; Mima, K.; Morikawa, T.; Song, M.; more...
    European Journal of Cancer (2019)

    Fulltext@MSK | Save
  • SMAD4 loss in colorectal cancer patients correlates with recurrence, loss of immune infiltrate, and chemoresistance
    Journal Article

    Wasserman, I.; Lee, L. H.; Ogino, S.; Marco, M. R.; Wu, C.; Chen, X.; Datta, J.; Sadot, E.; Szeglin, B.; Guillem, J. G.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Colorectal carcinomas containing hypermethylated MLH1 promoter and wild-type BRAF/KRAS are enriched for targetable kinase fusions
    Journal Article

    Cocco, E.; Benhamida, J.; Middha, S.; Zehir, A.; Mullaney, K.; Shia, J.; Yaeger, R.; Zhang, L.; Wong, D.; Villafania, L.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Nonthermal ablation of pancreatic cancer in a pig model, using vascular-targeted photodynamic therapy (VTP)
    Meeting Abstract

    Yarmohammadi, H.; Nurili, F.; Fujimori, M.; Monette, S.; Kelsen, D.; Coleman, J.; O'Reilly, E.; Schook, L.; Solomon, S.; Scherz, A.; more...
    Journal of Vascular and Interventional Radiology (2019)

    Fulltext@MSK | Save
  • Safety and toxicity of concurrent Y90 radioembolization and checkpoint-inhibitor immunotherapy
    Meeting Abstract

    Zhan, C.; Ruohoniemi, D.; Kulkarni, K.; Martirosyan, K.; Welling, T.; Gu, P.; Taslakian, B.; Hickey, R.
    Journal of Vascular and Interventional Radiology (2019)

    Fulltext@MSK | Save
  • CRISPR-mediated loss of DAXX protein expression in BON1 cell lines results in ischemia resistance and ischemia-induced epithelial-mesenchymal transition
    Meeting Abstract

    Morocho, P.; Cai, L.; Rizzo, A.; Felsenstein, M.; Boas, F.; Erinjeri, J.; Yarmohammadi, H.; Cross, J.; Solomon, S.; Heaphy, C.; more...
    Journal of Vascular and Interventional Radiology (2019)

    Fulltext@MSK | Save
  • A phase Ib, open-label study of dalantercept, an activin receptor-like kinase 1 ligand trap, plus sorafenib in advanced hepatocellular carcinoma
    Journal Article

    Abou-Alfa, G. K.; Miksad, R. A.; Tejani, M. A.; Williamson, S.; Gutierrez, M. E.; Olowokure, O. O.; Sharma, M. R.; El Dika, I.; Sherman, M. L.; Pandya, S. S.
    The Oncologist (2019)

    Fulltext@MSK | Save
  • RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling
    Research Letter

    Yao, Z.; Gao, Y.; Su, W.; Yaeger, R.; Tao, J.; Na, N.; Zhang, Y.; Zhang, C.; Rymar, A.; Tao, A.; more...
    Nature Medicine (2019)

    Fulltext@MSK | Save